Krystal Biotech, Inc. KRYS United States — Product revenue, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s united states — product revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s united states — product revenue, net?
- Krystal Biotech, Inc. (KRYS) reported united states — product revenue, net of $87.49M in Q1 2026.
- What does united states — product revenue, net mean?
- The total net sales of the company's products within the United States.
- How do you interpret united states — product revenue, net?
- An increase indicates successful market adoption, effective commercial execution, or expanded patient access, while a decrease may signal competitive pressure, pricing challenges, or lower-than-expected demand for the company's therapies.
- How does united states — product revenue, net compare across companies?
- Comparable to domestic net product sales reported by other commercial-stage biotechnology firms, often benchmarked against peers with orphan drug portfolios to evaluate revenue growth trajectories.